FTL and Alzheimer disease: On the other hand, it was observed a good concordance between antibody microarrays and mass-spectrometry data regarding to the alterations in the expression of 5 (FTL, LGALS3BP, MBL2, PRKCA, and PRKCG) of the 6 proteins identified using different quantitative mass-spectrometry approaches and samples from cortical areas, temporal neocortex, and hippocampus from AD patients and controls (Table 3) [49–54].